CN1230164C - (S)－2－(苄基氨基甲基)－2,3,8,9－四氢－7H－1,4－二英并[2,3－e]吲哚－8－酮和精神抑制药的用于治疗或预防精神病的新的治疗剂组合物 - Google Patents

(S)－2－(苄基氨基甲基)－2,3,8,9－四氢－7H－1,4－二英并[2,3－e]吲哚－8－酮和精神抑制药的用于治疗或预防精神病的新的治疗剂组合物 Download PDF

Info

Publication number
CN1230164C
CN1230164C CNB008169527A CN00816952A CN1230164C CN 1230164 C CN1230164 C CN 1230164C CN B008169527 A CNB008169527 A CN B008169527A CN 00816952 A CN00816952 A CN 00816952A CN 1230164 C CN1230164 C CN 1230164C
Authority
CN
China
Prior art keywords
antipsychotic drug
indol
application
pharmaceutical composition
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB008169527A
Other languages
English (en)
Chinese (zh)
Other versions
CN1409633A (zh
Inventor
K·L·马尔圭斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN1409633A publication Critical patent/CN1409633A/zh
Application granted granted Critical
Publication of CN1230164C publication Critical patent/CN1230164C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB008169527A 1999-12-10 2000-12-07 (S)－2－(苄基氨基甲基)－2,3,8,9－四氢－7H－1,4－二英并[2,3－e]吲哚－8－酮和精神抑制药的用于治疗或预防精神病的新的治疗剂组合物 Expired - Lifetime CN1230164C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45860799A 1999-12-10 1999-12-10
US09/458,607 1999-12-10

Publications (2)

Publication Number Publication Date
CN1409633A CN1409633A (zh) 2003-04-09
CN1230164C true CN1230164C (zh) 2005-12-07

Family

ID=23821437

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008169527A Expired - Lifetime CN1230164C (zh) 1999-12-10 2000-12-07 (S)－2－(苄基氨基甲基)－2,3,8,9－四氢－7H－1,4－二英并[2,3－e]吲哚－8－酮和精神抑制药的用于治疗或预防精神病的新的治疗剂组合物

Country Status (20)

Country Link
EP (1) EP1235570A2 (pl)
JP (1) JP5557409B2 (pl)
KR (1) KR100772854B1 (pl)
CN (1) CN1230164C (pl)
AR (1) AR026756A1 (pl)
AU (1) AU784211B2 (pl)
BR (1) BR0016168A (pl)
CA (1) CA2396351C (pl)
CZ (1) CZ20021880A3 (pl)
EA (1) EA005002B1 (pl)
HK (1) HK1045942A1 (pl)
HU (1) HUP0203309A3 (pl)
IL (2) IL149669A0 (pl)
MX (1) MXPA02005649A (pl)
NO (1) NO20022739D0 (pl)
NZ (1) NZ519381A (pl)
PL (1) PL355292A1 (pl)
TW (1) TWI222864B (pl)
WO (1) WO2001041750A2 (pl)
ZA (1) ZA200205484B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200517106A (en) 2003-10-29 2005-06-01 Wyeth Corp Sustained release pharmaceutical compositions
EP1856126A2 (en) 2005-02-17 2007-11-21 Wyeth a Corporation of the State of Delaware Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
JP2011511845A (ja) * 2008-02-13 2011-04-14 ターガセプト，インコーポレイテッド アルファ７（α７）ニコチン作動薬と抗精神病薬との組合せ物
HRP20220739T1 (hr) * 2020-05-04 2022-08-19 Bioprojet Pharma Upotreba dopaminskih d3 djelomičnih agonista za liječenje poremećaja središnjeg živčanog sustava
GB202014184D0 (en) 2020-09-09 2020-10-21 Johnson Matthey Plc Modifed catalyst supports and catalysts supported thereon

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2987484B2 (ja) * 1995-03-16 1999-12-06 大塚製薬 株式会社 カルボスチリル誘導体の製造方法
US5756532A (en) * 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
GB9627005D0 (en) * 1996-12-27 1997-02-12 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
AU784211B2 (en) 2006-02-23
CA2396351C (en) 2009-11-10
MXPA02005649A (es) 2004-09-10
EA005002B1 (ru) 2004-10-28
JP5557409B2 (ja) 2014-07-23
CA2396351A1 (en) 2001-06-14
IL149669A0 (en) 2002-11-10
WO2001041750A2 (en) 2001-06-14
EA200200656A1 (ru) 2002-12-26
NZ519381A (en) 2004-04-30
JP2003516350A (ja) 2003-05-13
CZ20021880A3 (cs) 2002-08-14
KR20030016207A (ko) 2003-02-26
EP1235570A2 (en) 2002-09-04
NO20022739L (no) 2002-06-07
TWI222864B (en) 2004-11-01
AR026756A1 (es) 2003-02-26
NO20022739D0 (no) 2002-06-07
HUP0203309A3 (en) 2004-12-28
KR100772854B1 (ko) 2007-11-02
WO2001041750A3 (en) 2002-02-14
BR0016168A (pt) 2002-08-20
ZA200205484B (en) 2003-12-31
HK1045942A1 (zh) 2002-12-20
PL355292A1 (pl) 2004-04-05
CN1409633A (zh) 2003-04-09
HUP0203309A2 (hu) 2003-01-28
AU1949001A (en) 2001-06-18
IL149669A (en) 2006-06-11

Similar Documents

Publication Publication Date Title
EP1994932A1 (en) Use of N-desmethylclozapine to treat human psychosis
US20090258084A1 (en) Mono and Combination Therapy with a M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Cognitive Disorders in Schizophrenia
WO2003066039A1 (en) Combination therapy for treatment of schizophrenia
US20090306040A1 (en) Mono and Combination Therapy of M1/M4 Agonist (Sabcomeline) for Treatment of Negative Symptoms of Schizophrenia
KR20010005677A (ko) 정신병성 질환의 치료 또는 예방을 위한 미르타자핀 및 항정신병제의 신규한 치료 조합물
US20070238725A1 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
US20060258639A1 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
CN1230164C (zh) (S)－2－(苄基氨基甲基)－2,3,8,9－四氢－7H－1,4－二英并[2,3－e]吲哚－8－酮和精神抑制药的用于治疗或预防精神病的新的治疗剂组合物
US20090318414A1 (en) Mono and Combination Therapy with M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Prodromal Syndrome
US6350773B1 (en) Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
AU2004246820B2 (en) Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight
CN1537007A (zh) 甲基-噻吩并-苯并二氮杂�的冻干制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20051207

CX01 Expiry of patent term